Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction.
- Author:
Yuan LIU
1
Author Information
1. Center of Reproductive Medicine, Nantong Maternity and Child Healthcare Hospital, Nantong, Jiangsu 226000, China. 1061097492@qq.com
- Publication Type:Journal Article
- MeSH:
Carbolines;
pharmacology;
therapeutic use;
Cardiovascular Diseases;
complications;
drug therapy;
Erectile Dysfunction;
complications;
drug therapy;
Humans;
Male;
Phosphodiesterase 5 Inhibitors;
pharmacology;
therapeutic use;
Tadalafil
- From:
National Journal of Andrology
2013;19(12):1147-1151
- CountryChina
- Language:Chinese
-
Abstract:
The enzyme phosphodiesterase-5 (PDE-5), widely distributed in the heart, smooth muscle, and blood vessels, catalyzes the hydrolysis of cyclic guanosine monophosphate (cGMP), a potent vasodilator, and is also a nitric oxide (NO) donor. Tadalafil is the first PDE 5 inhibitor approved by FDA for the treatment of ED. Recent studies have shown several pleiotropic beneficial effects of PDE-5 inhibitors in patients with cardiovascular diseases (coronary heart disease, hypertension, heart failure, and pulmonary arterial hypertension) and diabetes mellitus. It has been demonstrated that tadalafil can not only improve sexual function, but also elevate the endothelial cell-derived NO level, activate protein kinase A, upregulate the intracellular Ca2+ concentration, and improve hemodynamic indexes. Thus, the PDE-5 inhibitor tadalafil, with its cardiovascular-protective effect, can be a therapeutic option for the treatment of ED patients with cardiovascular disease.
